Newer Therapeutic Targets in Head and Neck Cancers

Sponsor
Banaras Hindu University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05382585
Collaborator
(none)
200
1
129
1.6

Study Details

Study Description

Brief Summary

Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes:

  1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA);

  2. cell-cycle control (e.g., CDKN2A and CCND1);

  3. cellular differentiation (e.g., NOTCH1); and

  4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways.

Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known

Condition or Disease Intervention/Treatment Phase
  • Other: Next generation Sequencing

Detailed Description

Sample size:

Patients with squamous cell carcinoma of oral cavity fulfilling the inclusion and exclusion criteria and willing to participate will be included in this study.

Method:

Comprehensive history and physical examination of the patients will be carried out and all the details will be recorded in the preset proforma. All routine investigations as indicated including a biopsy to establish a diagnosis and CT of the head and neck to measure the tumor dimensions and stage the disease before initiation of treatment will be recorded. The paraffin embedded tissue will be studied for expression of various genetic mutations using NGS platform. Brush cytology will be collected in liquid medium for HPV typing using PCR.

The Ion AmpliSeq™ Cancer Hotspot Panel v3 will be used to detect hotspot regions of 161 oncogenes and tumor suppressor genes This research panel, with improved primer design, contains 4,648 total 4 pools (DNA pool 1: 1,891 amplicons. DNA pool 2: 1,890 amplicons. RNA pool 1: 447 amplicons. RNA pool 2: 420 amplicons.), enabling researchers to sequence challenging samples of formalin-fixed, paraffin-embedded (FFPE) tissue. Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Polymorphisms (SNPs), Somatic Variants are identified.

HPV DNA PCR METHODOLOGY

DNA will be isolated by using QIAamp DNA mini kit (Qiagen, Hilden, Germany). The presence of HPV will be detected by using the digene® HC2 HPV DNA Test- The digene HC2 HPV DNA Test uses Hybrid Capture 2 technology to detect high-risk and low-risk HPV genotypes. It uses in vitro microplate assay based on signal-amplified nucleic acid hybridization that uses chemiluminescence for the qualitative detection of 18 types of human papillomavirus (HPV) (13 high risk and 5 low risk) DNA in cervical specimens. The test uses an RNA probe cocktail that detects 13 high-risk HPV types (16/18/31/33/35/39/45/51/52/56/58/59/68) and 5 low-risk types (6/11/42/43/44).

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers
Actual Study Start Date :
Apr 1, 2017
Anticipated Primary Completion Date :
Dec 31, 2027
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Head neck cancer

Histologically diagnosed cases of head and neck cancer

Other: Next generation Sequencing
Next generation sequencing for 161 genes

Outcome Measures

Primary Outcome Measures

  1. Over all survival [10 years]

    Survival time from the diagnosis to death

  2. Relapse free survival [10 years]

    survival time from diagnosis to recurrence or metastasis

Secondary Outcome Measures

  1. Progression free survival [5 years]

    The time from the diagnosis to progression of disease

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Histologically proven cases of primary head and neck cancers.
Exclusion Criteria:
  • Patients under 18 years of age

  • Pregnant and lactating women

  • Multiple cancers or patients with cancer of other sites.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Banaras Hindu University Varanasi UP India 221005

Sponsors and Collaborators

  • Banaras Hindu University

Investigators

  • Principal Investigator: Manoj Pandey, MS, PhD, Professor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Manoj Pandey, Professor, Banaras Hindu University
ClinicalTrials.gov Identifier:
NCT05382585
Other Study ID Numbers:
  • NGSHN1
First Posted:
May 19, 2022
Last Update Posted:
May 20, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Manoj Pandey, Professor, Banaras Hindu University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 20, 2022